January 4, 2018 / 5:44 PM / Updated 7 minutes ago BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated) Reuters Staff 1 Min Read 
Jan 4 (Reuters) - Catalyst Biosciences Inc: 
* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS 
* CATALYST BIOSCIENCES INC - ‍INTERIM DATA FOR PHASE 2 MARZAA TRIAL​ EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage: